Enterprise Value
704.3M
Cash
42.99M
Avg Qtr Burn
-5.652M
Short % of Float
0.03%
Insider Ownership
8.54%
Institutional Own.
1.44%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist) Details Multiple myeloma, Stem cell mobilization | Approved Quarterly sales | |
Motixafortide (BL-8040) w/ zimberelimab Details Pancreatic cancer, Cancer, Solid tumor/s | Phase 2/3 Data readout | |
Motixafortide (BL-8040) w/ cemiplimab Details Pancreatic cancer, Solid tumor/s, Cancer | Phase 2 Data readout | |
AGI-134 Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Motixafortide (BL-8040) +/- natalizumab Details Cancer, Blood disorder, Sickle cell disease | Phase 1 Data readout | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Solid tumor/s, Pancreatic cancer, Cancer | Failed Discontinued | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Acute myeloid leukemia | Failed Discontinued |